Time filter

Source Type

Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology | Kamiya H.,Aichi Medical University | Himeno T.,Aichi Medical University | Kato Y.,Aichi Medical University | And 9 more authors.
Internal Medicine | Year: 2017

Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients with type 2 diabetes mellitus with or without other antidiabetic drugs for 6 months to evaluate its efficacy, the incidence of adverse events, and its influence on the renal function. Results The patient’s mean glycated hemoglobin level significantly improved from 7.52±1.16% to 6.95± 0.98% (p<0.001). The body weight of the patients was significantly reduced from 78.0±15.3 kg to 75.6±15.1 kg (p<0.001). The estimated visceral fat area was also significantly reduced from 108.4±44.6 cm2 to 94.5± 45.3 cm2 (p<0.001). The waist circumference, blood pressure, serum alanine aminotransferase, γ-glutamyl transpeptidase, and uric acid levels also showed a significant decrease. The urinary albumin/creatinine ratio (U-ACR) was significantly reduced in the patients whose U-ACR levels were 30-300 mg/gCr at the baseline. The mean eGFR significantly decreased in the patients with a pre-treatment eGFR value of ≥90 mL/min/1.73 m2 but remained unchanged in the patients with a pre-treatment value of <90 mL/min/1.73 m2. A total of 13 adverse events were noted, including systemic eruption (n=1), cystitis (n=2), pudendal pruritus (n=2), nausea (n=1), malaise (n=1), a strong hunger sensation and increased food ingestion (n=1), and non-serious hypoglycemia (n=5). Conclusion SGLT2 inhibitors seemed to be useful in the treatment of obese type 2 diabetes mellitus patients. Furthermore, these data suggest that SGLT2 inhibitors may protect the renal function. © 2017 The Japanese Society of Internal Medicine.


Tosaki T.,TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology | Kamiya H.,Aichi Medical University | Kato Y.,Aichi Medical University | Kondo M.,Aichi Medical University | And 8 more authors.
Journal of the Japan Diabetes Society | Year: 2015

This study was conducted to investigate the efficacy and safety of a SGLT2 inhibitor, ipragliflozin, in Japanese patients with type 2 diabetes. Ipragliflozin was administered to a total of 89 out-patients treated with or without other oral hypoglycemic agents, insulin, or GLP-1 receptor agonists for 12 weeks. Significant decreases were observed in the HbA1c value from 7.46 ± 1.12 % to 7.02 ± 0.99 % (p<0.001), body weight from 76.4 ± 14.4 kg to 74.5 ± 14.2 kg (p<0.001), visceral fat mass from 100.4 ± 39.5 cm2 to 93.2 ± 33.7 cm2 (p= 0.011), systolic and diastolic blood pressure, waist circumference and the EGFR. As adverse events of ipragliflozin treatment, whole body eruption, cystitis and vaginal candidiasis in one case and non-severe hypoglycemia in 2 cases were observed. Ipragliflozin is relatively well-tolerated and effective for the treatment of Japanese obese patients with type 2 diabetes.

Loading TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology collaborators
Loading TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology collaborators